1. Theophylline produces bronchodilation through two pharmacologically distinct mechanisms that operate at different concentration ranges and produce different clinical consequences. Which of the following correctly identifies both mechanisms and accurately distinguishes the primary bronchodilatory mechanism from the secondary one?
A) The primary mechanism is non-competitive adenosine A1 receptor antagonism at airway smooth muscle, which directly prevents adenosine-mediated bronchoconstriction; the secondary mechanism is phosphodiesterase inhibition, which contributes only minimally to bronchodilation at therapeutic concentrations and is responsible mainly for anti-inflammatory effects
B) The primary mechanism is direct activation of beta-2 adrenergic receptors on airway smooth muscle, raising intracellular cAMP (cyclic adenosine monophosphate) through adenylyl cyclase stimulation; the secondary mechanism is adenosine receptor antagonism, which provides additional bronchodilation at supra-therapeutic concentrations
C) The primary mechanism at therapeutic concentrations is inhibition of PDE3 (phosphodiesterase 3) and PDE4 (phosphodiesterase 4) in airway smooth muscle and inflammatory cells, raising intracellular cAMP and reducing smooth muscle contractility; the secondary mechanism is non-competitive adenosine A1 and A2 receptor antagonism, which contributes to bronchodilation but is also responsible for the cardiac and CNS (central nervous system) toxicities seen at higher concentrations
D) Both mechanisms — PDE inhibition and adenosine receptor antagonism — are of equal clinical importance at therapeutic serum concentrations; the distinction between primary and secondary is a historical artifact with no pharmacokinetic basis, since both mechanisms are fully operational across the entire 10–20 mcg/mL therapeutic range
E) The primary mechanism is selective PDE4 inhibition in inflammatory cells, producing anti-inflammatory effects; the secondary mechanism is selective PDE3 inhibition in airway smooth muscle, producing bronchodilation; adenosine receptor antagonism is a pharmacologically irrelevant off-target effect that does not contribute to either the therapeutic or toxic profile of theophylline
ANSWER: C
Rationale:
Theophylline operates through two mechanistically distinct pathways. The primary bronchodilatory mechanism at therapeutic serum concentrations is inhibition of PDE3 and PDE4 — the phosphodiesterase isoforms responsible for degrading cyclic AMP (cAMP) in airway smooth muscle and inflammatory cells. PDE inhibition raises intracellular cAMP, activates protein kinase A (PKA), phosphorylates myosin light chain kinase, and reduces airway smooth muscle contractility. PDE4 inhibition in inflammatory cells provides the modest anti-inflammatory benefit that complements bronchodilation. The secondary mechanism — non-competitive antagonism of adenosine A1 and A2 receptors — contributes to bronchodilation (adenosine normally promotes bronchoconstriction via A1 receptors on airway smooth muscle and mast cell degranulation via A2B receptors), but adenosine receptor antagonism at higher concentrations is also the primary driver of theophylline's most dangerous toxicities: tachycardia and arrhythmias via A1 blockade at the SA (sinoatrial) and AV (atrioventricular) nodes, and seizures via A1 blockade in the CNS.
Option A: Option A is incorrect because it inverts the primary and secondary mechanisms; PDE inhibition — not adenosine receptor antagonism — is the primary bronchodilatory mechanism at therapeutic concentrations; adenosine antagonism is secondary and also toxicologically significant.
Option B: Option B is incorrect because theophylline does not activate beta-2 adrenergic receptors; beta-2 agonists stimulate adenylyl cyclase directly, whereas theophylline prevents cAMP breakdown — these are pharmacologically distinct mechanisms with different receptor targets.
Option D: Option D is incorrect because the two mechanisms are not of equal importance at therapeutic concentrations; PDE inhibition is established as the primary bronchodilatory mechanism at the 10–20 mcg/mL range, while adenosine receptor antagonism assumes increasing pharmacological and toxicological significance at concentrations at and above the upper therapeutic boundary.
Option E: Option E is incorrect because both PDE3 and PDE4 contribute to theophylline's bronchodilatory and anti-inflammatory effects, respectively — they are not sequentially primary and secondary; and adenosine receptor antagonism is not pharmacologically irrelevant — it is the mechanistic basis for theophylline's dangerous cardiac and CNS toxicity profile.
2. A 64-year-old woman with COPD (chronic obstructive pulmonary disease) has been stable on the same theophylline dose for 18 months with a serum level of 14 mcg/mL. She is admitted with an acute decompensated heart failure exacerbation. Over the next 48 hours she develops nausea, tremor, and a theophylline level of 26 mcg/mL without any change in her theophylline dose. Which pharmacokinetic principle most precisely explains this clinical scenario?
A) At concentrations near the upper therapeutic range, theophylline elimination operates near the saturation point of hepatic CYP1A2 (cytochrome P450 1A2); when heart failure reduces hepatic blood flow and further impairs CYP1A2 activity, elimination shifts further toward zero-order kinetics, causing disproportionate concentration accumulation without any dose change
B) Heart failure activates the renin-angiotensin-aldosterone system, which directly inhibits CYP1A2 through angiotensin II receptor-mediated transcriptional suppression of cytochrome P450 enzyme genes in hepatocytes
C) The reduced cardiac output of heart failure exacerbation causes theophylline to redistribute from peripheral tissues back into the central compartment, raising plasma concentrations without altering total body drug content or elimination kinetics
D) Acute heart failure increases inflammatory cytokine levels, which upregulate P-glycoprotein expression in the gut wall and reduce theophylline absorption from its slow-release formulation, paradoxically causing erratic concentration swings rather than a sustained rise
E) Heart failure produces peripheral edema that expands theophylline's apparent volume of distribution (Vd), initially diluting serum concentrations; subsequent diuretic therapy corrects the edema but overshoots, concentrating theophylline in a contracted intravascular volume and producing toxicity
ANSWER: A
Rationale:
Theophylline's elimination follows first-order kinetics at lower serum concentrations but shifts toward Michaelis-Menten (zero-order, saturable) kinetics as concentrations approach and exceed the therapeutic range. At a stable level of 14 mcg/mL, this patient's hepatic CYP1A2-mediated metabolism was operating near — but not yet at — full saturation. Acute decompensated heart failure reduces cardiac output and consequently reduces hepatic blood flow; reduced hepatic perfusion impairs first-pass and systemic CYP1A2-mediated theophylline clearance. When clearance falls at a concentration already near the saturation threshold, the system tips into more pronounced zero-order elimination behavior, and a small reduction in clearance produces a disproportionately large rise in steady-state concentration. This is why the level nearly doubled (14 → 26 mcg/mL) without any dose change.
Option B: Option B is incorrect because the renin-angiotensin-aldosterone system does not directly regulate CYP1A2 through angiotensin II receptor-mediated transcriptional suppression; while cytokines and heart failure can modulate CYP expression through indirect mechanisms, the primary and most clinically important mechanism of reduced theophylline clearance in heart failure is reduced hepatic blood flow, not angiotensin-driven enzyme suppression.
Option C: Option C is incorrect because theophylline does not undergo significant redistribution from peripheral compartments back to plasma during heart failure exacerbation in a manner that would account for a near-doubling of plasma concentration; redistribution-driven concentration changes occur with drugs that have very large volumes of distribution and are typically transient, not sustained.
Option D: Option D is incorrect because heart failure does not upregulate P-glycoprotein in the gut wall in a manner that reduces theophylline absorption; theophylline is not a P-glycoprotein substrate of clinical significance, and the described mechanism is pharmacologically inaccurate.
Option E: Option E is incorrect because theophylline's volume of distribution does not change substantially with peripheral edema — the drug is primarily distributed in body water, and the described mechanism of edema-then-diuresis causing concentration swings is not the established explanation for theophylline toxicity in heart failure; the primary mechanism is reduced hepatic clearance due to diminished hepatic blood flow.
3. A hospitalist must manage two different patients on theophylline for severe COPD (chronic obstructive pulmonary disease). Patient 1 is started on ciprofloxacin for a urinary tract infection. Patient 2 is started on rifampin for latent tuberculosis treatment. Which of the following correctly predicts the direction of the theophylline level change in each patient and identifies the mechanism responsible?
A) Patient 1: theophylline levels will fall because ciprofloxacin induces CYP1A2 (cytochrome P450 1A2), increasing theophylline clearance; Patient 2: theophylline levels will rise because rifampin inhibits CYP3A4 (cytochrome P450 3A4), reducing theophylline metabolism through its minor pathway
B) Patient 1: theophylline levels will rise modestly (10–15%) due to mild CYP3A4 inhibition by ciprofloxacin; Patient 2: theophylline levels will fall modestly (10–15%) due to mild CYP1A2 induction by rifampin; neither change is clinically significant at standard theophylline doses
C) Both patients will experience rising theophylline levels: ciprofloxacin and rifampin are both CYP1A2 inhibitors, and their co-administration with theophylline requires dose reduction and serum level monitoring in both cases
D) Patient 1: theophylline levels will rise significantly (30–50%) because ciprofloxacin inhibits CYP1A2, the primary theophylline-metabolizing enzyme, requiring dose reduction and close level monitoring; Patient 2: theophylline levels will fall significantly (50–75%) because rifampin is a potent inducer of CYP1A2 and CYP3A4, requiring substantial theophylline dose increases during co-administration and careful monitoring after rifampin is discontinued
E) Patient 1: theophylline levels will remain unchanged because fluoroquinolones selectively inhibit bacterial topoisomerase II without any effect on mammalian CYP enzymes; Patient 2: theophylline levels will fall because rifampin induces hepatic UDP-glucuronosyltransferase (UGT) enzymes that conjugate theophylline for renal excretion
ANSWER: D
Rationale:
Ciprofloxacin and rifampin have opposite and clinically significant effects on theophylline serum concentrations, both mediated through CYP1A2 — theophylline's primary metabolic enzyme. Ciprofloxacin inhibits CYP1A2 and reduces theophylline clearance by approximately 30–50%, producing a corresponding rise in serum theophylline concentrations that can precipitate toxicity within days of starting the antibiotic; the clinical response is theophylline dose reduction plus serum level monitoring. Rifampin is a potent inducer of both CYP1A2 and CYP3A4 and can reduce theophylline serum concentrations by 50–75%, requiring substantial dose increases during co-administration; critically, when rifampin is discontinued, CYP induction wanes over 1–2 weeks and theophylline clearance falls back toward baseline — if the elevated dose is not reduced at that point, toxicity can develop.
Option A: Option A is incorrect because it reverses the directions of both interactions: ciprofloxacin inhibits (does not induce) CYP1A2, causing theophylline levels to rise, not fall; rifampin induces (does not inhibit) CYP1A2 and CYP3A4, causing theophylline levels to fall, not rise.
Option B: Option B is incorrect because it dramatically understates the magnitude of both interactions; ciprofloxacin can increase theophylline levels by 30–50% (not 10–15%), and rifampin can reduce them by 50–75% (not 10–15%); both changes are clinically significant and require active management.
Option C: Option C is incorrect because rifampin is a potent CYP inducer, not an inhibitor; co-administration with theophylline requires dose increases (not dose reduction) and produces falling, not rising, theophylline concentrations.
Option E: Option E is incorrect because ciprofloxacin does significantly inhibit mammalian CYP1A2 in addition to its antibacterial mechanism; the fluoroquinolone mechanism of action against bacterial topoisomerase II does not confer CYP neutrality in human hepatocytes; and theophylline is metabolized primarily by CYP1A2, not by UGT conjugation enzymes.
4. A 71-year-old man with COPD (chronic obstructive pulmonary disease) presents with multifocal atrial tachycardia, a theophylline level of 36 mcg/mL, and a serum potassium of 2.9 mEq/L. A medical student asks how theophylline simultaneously produces cardiac arrhythmias and hypokalemia through related mechanisms. Which of the following is the most accurate mechanistic explanation?
A) Theophylline inhibits Na-K-ATPase in cardiac myocytes, increasing intracellular sodium and reducing intracellular potassium, thereby raising the resting membrane potential toward the threshold for spontaneous depolarization; the same Na-K-ATPase inhibition in renal tubular cells reduces potassium reabsorption and causes renal potassium wasting
B) Theophylline's adenosine A1 receptor antagonism removes adenosine's normal inhibitory restraint on SA (sinoatrial) node automaticity and AV (atrioventricular) conduction, directly promoting tachyarrhythmias; simultaneously, theophylline-stimulated catecholamine release activates beta-2 adrenergic receptors on skeletal muscle, driving potassium into cells via Na-K-ATPase activation and producing a transcellular hypokalemia that lowers the ventricular arrhythmia threshold
C) Theophylline inhibits PDE3 (phosphodiesterase 3) in cardiac pacemaker cells, raising intracellular cAMP (cyclic adenosine monophosphate) to supraphysiological levels; the resulting PKA (protein kinase A) activation phosphorylates cardiac L-type calcium channels, producing calcium overload and triggered arrhythmias; hypokalemia is caused by theophylline-mediated aldosterone secretion that promotes renal potassium excretion
D) Theophylline directly blocks cardiac potassium channels (IKr), prolonging the QT interval and creating conditions for re-entrant ventricular arrhythmias; hypokalemia results from theophylline-induced ADH (antidiuretic hormone) suppression, causing a mild diabetes insipidus with free water loss and secondary electrolyte disturbance
E) Theophylline blocks adenosine A2A receptors in coronary arteries, reducing coronary vasodilation and producing demand ischemia in the setting of tachycardia; the resulting catecholamine stress response causes renal potassium wasting through cortisol-mediated mineralocorticoid receptor activation in the distal nephron
ANSWER: B
Rationale:
Theophylline's cardiac toxicity and hypokalemia share a linked mechanistic origin rooted in adenosine receptor antagonism and catecholamine release. The cardiac arrhythmias arise directly from adenosine A1 receptor antagonism: adenosine normally restrains SA node automaticity and slows AV conduction through inhibitory Gi protein signaling; theophylline's A1 blockade removes this restraint, increasing heart rate and promoting tachyarrhythmias. Multifocal atrial tachycardia is particularly characteristic of theophylline toxicity in patients with underlying lung disease. Theophylline also stimulates catecholamine (primarily epinephrine) release from the adrenal medulla. The resulting adrenergic surge activates beta-2 adrenergic receptors on skeletal muscle, which stimulate Na-K-ATPase to drive potassium into cells — a transcellular shift that reduces serum potassium without renal potassium loss. This hypokalemia lowers the threshold for ventricular arrhythmias, compounding the direct arrhythmogenic effect of adenosine A1 antagonism.
Option A: Option A is incorrect because Na-K-ATPase inhibition in cardiac myocytes and renal tubular cells is the mechanism of digoxin toxicity, not theophylline toxicity; theophylline does not inhibit Na-K-ATPase, and the hypokalemia seen with theophylline is a transcellular shift driven by beta-2 adrenergic stimulation, not a renal wasting process.
Option C: Option C is incorrect because while PDE3 inhibition does contribute to theophylline's bronchodilatory mechanism, the arrhythmias at toxic concentrations are not primarily driven by PDE3-mediated cAMP elevation in cardiac pacemaker cells — adenosine receptor antagonism is the dominant cardiac toxicity mechanism; furthermore, theophylline-induced hypokalemia is not mediated by aldosterone secretion but by beta-2-driven transcellular potassium shift.
Option D: Option D is incorrect because theophylline does not directly block cardiac IKr potassium channels (hERG channels) — that is the mechanism of QT-prolonging drugs such as certain antipsychotics and antibiotics; and theophylline does not suppress ADH to a degree that produces clinically significant free water loss accounting for hypokalemia.
Option E: Option E is incorrect because while A2A receptor antagonism at coronary arteries is a pharmacological property of theophylline, demand ischemia-driven cortisol release causing renal potassium wasting is not the established mechanism for theophylline-associated hypokalemia; the beta-2-mediated transcellular shift mechanism is well established and directly accounts for the clinical finding.
5. A 58-year-old man with COPD (chronic obstructive pulmonary disease) who smokes one pack per day is maintained on sustained-release theophylline 700 mg daily with a stable serum level of 15 mcg/mL. He calls his physician to report that he has just stopped smoking using varenicline and asks whether any medication adjustment is needed. Which of the following represents the most appropriate clinical response and correctly explains the pharmacokinetic basis for the required action?
A) No dose change is needed immediately; serum theophylline levels should be rechecked in six months once the patient's lung function has stabilized on a smoke-free regimen, at which point any dose adjustment can be made electively
B) The theophylline dose should be increased by 30–40% immediately upon smoking cessation because nicotine withdrawal reduces airway responsiveness and the patient will require higher systemic theophylline concentrations to achieve the same degree of bronchodilation
C) The theophylline dose should be held entirely for 48 hours after the last cigarette to allow nicotine to clear from the system, then resumed at the same dose once a new steady-state serum level confirms the level remains within the therapeutic range
D) Varenicline directly inhibits CYP1A2 (cytochrome P450 1A2) through its nicotinic receptor partial agonist mechanism; the theophylline dose should be reduced by 50% immediately upon starting varenicline regardless of whether the patient successfully quits smoking
E) The theophylline dose should be proactively reduced — by approximately 30–50% — before theophylline levels rise, because smoking cessation causes CYP1A2 induction from polycyclic aromatic hydrocarbons to wane progressively over 1–2 weeks; serum levels must be monitored closely during this transition to avoid toxicity at the previously adequate dose
ANSWER: E
Rationale:
Polycyclic aromatic hydrocarbons (PAHs) in tobacco smoke are the component responsible for CYP1A2 induction — not nicotine itself. When a patient who smokes quits, PAH exposure ceases and CYP1A2 induction diminishes progressively over approximately 1–2 weeks as hepatic enzyme expression returns toward non-smoker baseline levels. As CYP1A2 activity falls, theophylline clearance decreases proportionally, and serum concentrations rise at the previously stable dose. The appropriate clinical response is proactive theophylline dose reduction — anticipating the pharmacokinetic change before toxicity develops — combined with serum level monitoring during the transition. Waiting for symptoms of toxicity to appear before acting is an avoidable error. The dose reduction required is approximately 30–50% in most patients, reflecting the magnitude of the CYP1A2 induction effect attributable to smoking.
Option A: Option A is incorrect because delaying reassessment to six months is clinically dangerous; CYP1A2 induction begins to wane within days of cessation and theophylline levels can rise to toxic concentrations within 1–2 weeks; a six-month delay is entirely inadequate and would predictably result in theophylline toxicity.
Option B: Option B is incorrect because the pharmacokinetic change after smoking cessation reduces theophylline clearance, causing levels to rise — requiring dose reduction, not dose increase; bronchodilatory target concentrations do not change with smoking status.
Option C: Option C is incorrect because holding theophylline for 48 hours is not an appropriate or established management strategy; nicotine clearance is irrelevant to the theophylline-CYP1A2 interaction (it is PAH-driven induction that matters, not nicotine); and resuming the same dose after a brief hold leaves the fundamental problem — reduced clearance — unaddressed.
Option D: Option D is incorrect because varenicline is a partial agonist at nicotinic acetylcholine receptors and does not inhibit CYP1A2; the theophylline interaction risk is from cessation of PAH-driven CYP1A2 induction, which occurs when smoking stops regardless of what pharmacological aid is used; varenicline itself has no clinically significant effect on theophylline pharmacokinetics.
6. A pulmonology fellow is reviewing the leukotriene biosynthesis pathway to understand why different inflammatory cells generate different leukotriene profiles and why this matters for selecting pharmacological targets. Which of the following correctly describes the LTA4 (leukotriene A4) branch point and accurately links each downstream product to its principal inflammatory cell source and clinical phenotype?
A) LTA4 is cleaved by LTA4 synthase into LTB4 in eosinophils and by LTC4 hydrolase into LTC4 in neutrophils; LTB4 drives eosinophilic airway inflammation in asthma while LTC4 mediates neutrophilic inflammation in COPD (chronic obstructive pulmonary disease) exacerbations
B) LTA4 is a stable intermediate that accumulates in the cell cytoplasm until exported to other cells via specific membrane transporters; once exported, adjacent structural cells convert LTA4 to either LTB4 or LTC4 depending on the receiving cell type, explaining why leukotriene profiles differ by tissue compartment rather than by cell of origin
C) LTA4 is the branch point intermediate: LTA4 hydrolase converts LTA4 to LTB4, which is produced primarily in neutrophils and acts as a potent neutrophil chemoattractant via BLT1 (leukotriene B4 receptor 1) receptors — relevant in COPD and severe neutrophilic asthma; LTC4 synthase conjugates LTA4 with glutathione to form LTC4 primarily in mast cells and eosinophils, generating the cysteinyl leukotriene series that drives eosinophilic bronchoconstriction, edema, and mucus hypersecretion in allergic asthma
D) Both LTB4 and LTC4 are produced from LTA4 by the same enzyme, 5-LOX (5-lipoxygenase), using glutathione as the branching substrate; LTB4 is the glutathione-free product and LTC4 is the glutathione-conjugated product; both are produced in equal proportions in all inflammatory cells
E) LTA4 is converted to LTB4 exclusively in mast cells via LTA4 hydrolase and to LTC4 exclusively in neutrophils via LTC4 synthase; this cell-specific distribution explains why antihistamines — which block mast cell histamine release — also reduce LTB4 production in mast cells while having no effect on LTC4 in neutrophils
ANSWER: C
Rationale:
LTA4 is the pivotal unstable epoxide intermediate in leukotriene biosynthesis that determines the downstream leukotriene profile based on which enzyme acts on it. LTA4 hydrolase converts LTA4 to LTB4 — this pathway predominates in neutrophils. LTB4 signals through BLT1 (leukotriene B4 receptor 1) receptors on neutrophils and BLT2 receptors on mast cells and eosinophils, acting as a potent neutrophil chemoattractant and driver of neutrophilic inflammation; LTB4 is particularly relevant in COPD and in severe asthma with a neutrophilic phenotype. Alternatively, LTC4 synthase conjugates LTA4 with glutathione to form LTC4 — this pathway predominates in mast cells and eosinophils. LTC4 is then sequentially cleaved extracellularly to LTD4 and LTE4 (the cysteinyl leukotriene series), which act at CysLT1 receptors to drive bronchoconstriction, airway edema, mucus hypersecretion, and eosinophil recruitment — the central pathophysiology of allergic asthma. Zileuton, as a 5-LOX inhibitor, suppresses both branches by preventing LTA4 formation; CysLT1 antagonists selectively block only the cysteinyl leukotriene arm at the receptor level.
Option A: Option A is incorrect because it reverses the cellular sources and downstream pathways: LTB4 is produced primarily in neutrophils (not eosinophils) and drives neutrophilic inflammation (relevant to COPD); LTC4 is produced primarily in mast cells and eosinophils (not neutrophils) and drives eosinophilic bronchoconstriction in asthma.
Option B: Option B is incorrect because LTA4 is an unstable intracellular epoxide that can undergo transcellular metabolism (export to adjacent cells) to some extent, but the description that LTA4 "accumulates and is exported" as its primary fate — rather than being immediately enzymatically converted — does not accurately represent the pathway; the branch point is defined by which enzyme acts first within the producing cell.
Option D: Option D is incorrect because LTB4 and LTC4 are produced by two distinct enzymes with different substrates: LTA4 hydrolase (which requires only LTA4) and LTC4 synthase (which requires LTA4 plus glutathione); 5-LOX produces LTA4 from AA but does not itself determine the LTB4/LTC4 split; and the two products are not generated in equal proportions by all inflammatory cells.
Option E: Option E is incorrect because LTB4 is produced primarily in neutrophils (not mast cells) and LTC4 is produced primarily in mast cells and eosinophils (not neutrophils); the attribution of antihistamine effects on leukotriene production is also pharmacologically incorrect — antihistamines block histamine H1 receptors and have no direct effect on leukotriene synthetic enzymes.
7. A clinical pharmacologist is asked to explain why montelukast and zafirlukast — selective CysLT1 (cysteinyl leukotriene receptor 1) antagonists — do not fully suppress all leukotriene-mediated effects in the airway and why this pharmacological limitation has implications for their positioning in asthma step therapy. Which of the following most accurately explains the receptor distribution pattern and its clinical consequences?
A) CysLT1 receptors are expressed on airway smooth muscle, bronchial epithelium, eosinophils, and mast cells and mediate bronchoconstriction, airway edema, mucus secretion, and eosinophil recruitment; CysLT2 receptors are expressed primarily in cardiac tissue, adrenal gland, and lung macrophages and mediate vascular permeability effects not blocked by available LTRAs (leukotriene receptor antagonists); furthermore, LTRAs do not affect LTB4-mediated neutrophilic inflammation, which signals through BLT1 (leukotriene B4 receptor 1) receptors, explaining their incomplete suppression of leukotriene biology and their role as add-on rather than monotherapy agents in moderate-to-severe asthma
B) CysLT1 and CysLT2 receptors have identical airway distribution and signaling but differ in their affinity for leukotriene subtypes; LTRAs block only CysLT1, which binds LTD4 (leukotriene D4) and LTC4, while CysLT2 — which binds LTE4 (leukotriene E4) exclusively — remains unblocked; since LTE4 is the most stable cysteinyl leukotriene and has the longest plasma half-life, its continued activity at CysLT2 accounts for incomplete bronchoconstriction suppression
C) LTRAs provide incomplete suppression because CysLT1 is expressed only on mast cells and not on airway smooth muscle itself; bronchoconstriction occurs when leukotriene-activated mast cells release histamine, which then acts on airway smooth muscle H1 receptors — a pathway that LTRAs interrupt only partially because they block mast cell activation but not the downstream histamine signaling
D) Available LTRAs block CysLT1 receptors competitively but with relatively low affinity; at high leukotriene concentrations generated during severe asthma attacks, receptor occupancy falls below the therapeutic threshold and unblocked CysLT1 activation resumes; this concentration-dependent loss of efficacy explains why LTRAs are inadequate as monotherapy in moderate-to-severe disease
E) CysLT1 and CysLT2 are co-expressed on all airway inflammatory cells in a fixed 1:1 ratio; currently available LTRAs block only CysLT1 and leave CysLT2 fully active; since CysLT2 has higher intrinsic coupling efficiency to Gq (guanine nucleotide-binding protein subunit q) signaling than CysLT1, the unblocked CysLT2 activation actually amplifies bronchoconstriction beyond baseline levels during LTRA therapy
ANSWER: A
Rationale:
The incomplete suppression of leukotriene-mediated effects by available LTRAs reflects two distinct gaps in pharmacological coverage. First, CysLT1 and CysLT2 have different tissue distributions: CysLT1 is the primary bronchopulmonary receptor, expressed on airway smooth muscle, bronchial epithelium, eosinophils, and mast cells, and its blockade by montelukast or zafirlukast produces clinically meaningful bronchodilation, reduced airway hyperresponsiveness, and attenuation of the allergic response. CysLT2, by contrast, is expressed primarily in cardiac tissue, adrenal gland, and lung macrophages; it mediates vascular permeability effects, and available LTRAs do not block it — though CysLT2's contribution to airway bronchoconstriction is secondary. Second and more clinically important: neither CysLT1 antagonists nor any currently available LTRAs affect LTB4-mediated neutrophilic inflammation, which signals through entirely separate BLT1 and BLT2 receptors. Only zileuton — acting upstream at 5-LOX — suppresses LTB4 synthesis and its pro-neutrophilic effects. This dual gap explains why LTRAs are positioned as add-on rather than monotherapy agents in moderate-to-severe asthma, where ICS-resistant neutrophilic and non-eosinophilic disease components require broader anti-inflammatory coverage.
Option B: Option B is incorrect because CysLT1 and CysLT2 are not identically distributed in the airway, and their pharmacological profiles differ beyond simply leukotriene subtype affinity; LTE4 does not signal exclusively through CysLT2, and the biological significance of CysLT2 in airway smooth muscle contraction is substantially less than that of CysLT1.
Option C: Option C is incorrect because CysLT1 is expressed directly on airway smooth muscle, where its activation by LTD4 via Gq/IP3/calcium signaling produces direct bronchoconstriction independent of mast cell histamine release; the characterization that LTRAs work only indirectly through mast cells is pharmacologically inaccurate.
Option D: Option D is incorrect because montelukast and zafirlukast are high-affinity competitive antagonists at CysLT1 with clinical efficacy well established in human trials; the characterization of "relatively low affinity" leading to concentration-dependent loss of receptor occupancy during severe attacks does not reflect the established pharmacological profile of these agents.
Option E: Option E is incorrect because CysLT1 and CysLT2 are not co-expressed on all airway inflammatory cells in a fixed 1:1 ratio — their tissue distributions are distinct; and CysLT2 activation does not amplify bronchoconstriction beyond baseline during LTRA therapy; this option describes a paradoxical worsening effect for which there is no pharmacological or clinical evidence.
8. A pharmacist is counseling two patients newly started on CysLT1 (cysteinyl leukotriene receptor 1) antagonists. Patient A has been prescribed montelukast and Patient B has been prescribed zafirlukast. The pharmacist needs to provide accurate, drug-specific counseling about dosing schedule, food interactions, metabolic pathways, and drug interaction risks. Which of the following correctly distinguishes the two agents across all four of these parameters?
A) Montelukast: once daily in the morning, take with a high-fat meal to maximize absorption, metabolized by CYP2C9 (cytochrome P450 2C9), significant interaction with warfarin requiring INR (international normalized ratio) monitoring; Zafirlukast: once daily in the evening, no food effect, metabolized by CYP3A4 (cytochrome P450 3A4) and CYP2C8, no significant drug interactions reported at standard doses
B) Montelukast: twice daily with food, metabolized by CYP2C9, inhibits CYP3A4 at clinical concentrations causing interactions with statins and cyclosporine, requires liver function test monitoring for hepatotoxicity risk; Zafirlukast: once daily in the evening, no food effect, metabolized by CYP3A4 and CYP2C8, no liver function monitoring required
C) Montelukast and zafirlukast are pharmacokinetically interchangeable; both are dosed once daily, both are metabolized primarily by CYP3A4, both require empty-stomach administration for adequate bioavailability, and neither has clinically significant drug interactions at standard therapeutic doses
D) Montelukast: once daily in the evening, no significant food effect, metabolized primarily by CYP3A4 (cytochrome P450 3A4) and CYP2C8, no routine liver function monitoring required, no clinically significant warfarin interaction; Zafirlukast: twice daily on an empty stomach (food reduces bioavailability approximately 40%), metabolized by CYP2C9, inhibits CYP2C9 and CYP3A4 at clinical concentrations causing a clinically significant warfarin interaction requiring INR monitoring
E) Montelukast: once daily in the evening, metabolized by CYP3A4 and CYP2C8, associated with Churg-Strauss syndrome-like vasculitis upon corticosteroid tapering, requires baseline and quarterly liver function monitoring; Zafirlukast: once daily in the morning with food, metabolized by CYP2C9, carries the FDA neuropsychiatric boxed warning for suicidality and mood disturbance
ANSWER: D
Rationale:
Montelukast and zafirlukast are both selective CysLT1 antagonists but differ substantially in pharmacokinetics, dosing requirements, and drug interaction profiles. Montelukast is administered once daily in the evening (to align with nocturnal patterns of leukotriene production and nocturnal asthma), has no clinically significant food effect, is metabolized primarily by CYP3A4 and CYP2C8, requires no routine liver function test monitoring, and does not significantly inhibit CYP2C9 at clinical concentrations — meaning no clinically meaningful warfarin interaction. Zafirlukast is dosed twice daily (20 mg twice daily in adults) and must be taken on an empty stomach because food reduces its oral bioavailability by approximately 40%. It is metabolized primarily by CYP2C9 and inhibits both CYP2C9 and CYP3A4 at clinical concentrations; CYP2C9 inhibition raises plasma concentrations of S-warfarin (the more potent enantiomer), producing a clinically significant increase in INR that requires monitoring whenever zafirlukast is added to stable warfarin therapy.
Option A: Option A is incorrect because it reverses the metabolic pathways and drug interaction profiles of the two agents; montelukast is metabolized by CYP3A4/CYP2C8 and does not cause the warfarin interaction, while zafirlukast is metabolized by CYP2C9 and does inhibit CYP2C9 causing the warfarin interaction; the morning/evening dosing and food requirements are also reversed.
Option B: Option B is incorrect because montelukast is dosed once daily (not twice daily), is metabolized by CYP3A4/CYP2C8 (not CYP2C9), and does not require liver function monitoring; the hepatotoxicity and LFT monitoring requirement belongs to zileuton, not montelukast or zafirlukast.
Option C: Option C is incorrect because the two agents are not pharmacokinetically interchangeable; they differ in dosing frequency (once vs. twice daily), food effect (minimal vs. 40% reduction), metabolic pathways (CYP3A4/2C8 vs. CYP2C9), and drug interaction profiles; zafirlukast requires empty-stomach administration while montelukast does not.
Option E: Option E is incorrect because the Churg-Strauss syndrome-like vasculitis upon corticosteroid tapering is associated with zafirlukast (not montelukast), and the FDA neuropsychiatric boxed warning for suicidality and mood disturbance belongs to montelukast (not zafirlukast); the liver function monitoring requirement applies to zileuton, not to either of these agents.
9. A 19-year-old college student with mild intermittent asthma and seasonal allergic rhinitis is seen in a student health clinic. The physician considers montelukast for combined symptom management. The student asks about serious risks she may have heard about with this drug. Which of the following best characterizes the FDA (Food and Drug Administration) boxed warning for montelukast and identifies the correct prescribing guidance it generates for this specific patient?
A) The boxed warning concerns QTc interval prolongation and ventricular arrhythmia; it applies only to patients over 65 years with pre-existing cardiac conduction disease; the student is not in the at-risk group and montelukast can be prescribed without any additional counseling or monitoring in her age group
B) The boxed warning, issued in March 2020, concerns serious neuropsychiatric events — including agitation, depression, suicidal ideation, hallucinations, and tremor — occurring across all age groups including young adults; the proposed mechanism involves CNS (central nervous system) CysLT1 (cysteinyl leukotriene receptor 1) receptor blockade; for this patient with mild disease where effective alternatives exist (intranasal corticosteroids, antihistamines, SABA as needed), the warning specifically recommends trying other therapies first; if montelukast is chosen, she must be counseled on neuropsychiatric risks and instructed to discontinue and contact her prescriber if symptoms develop
C) The boxed warning concerns irreversible bronchoconstriction in patients with mild asthma who receive montelukast as monotherapy; the warning states that montelukast must always be co-administered with an ICS (inhaled corticosteroid) and is absolutely contraindicated as a single agent in any patient with mild or intermittent asthma
D) The boxed warning concerns hepatocellular injury identical to that associated with zileuton; baseline liver function tests are required before initiating montelukast in all patients and monthly monitoring is required for the first year, regardless of age or disease severity
E) The boxed warning concerns systemic vasculitis resembling Churg-Strauss syndrome in patients on concurrent systemic corticosteroids; the warning is applicable only to patients who are also receiving prednisone or other systemic corticosteroids and does not apply to this patient who is not on systemic steroid therapy
ANSWER: B
Rationale:
The FDA issued a boxed warning for montelukast in March 2020 regarding serious neuropsychiatric adverse events, including agitation, aggression, anxiousness, dream abnormalities and hallucinations, depression, insomnia, irritability, restlessness, suicidal thinking and behavior (suicidality), and tremor. These events have been reported in patients across all age groups — including children, adolescents, and adults — not only in older or higher-risk populations. The proposed (though not fully established) mechanism involves montelukast or its metabolites crossing the blood-brain barrier (BBB) and blocking CysLT1 receptors in the CNS, where they appear to participate in neuroinflammatory signaling. The FDA prescribing guidance specifically states that for patients with mild asthma or allergic rhinitis — where effective alternative therapies exist — the neuropsychiatric risk should be carefully weighed against the benefit and other therapies should be considered first. This student's mild intermittent asthma and seasonal rhinitis represent exactly the indication category the warning targets; intranasal corticosteroids, oral antihistamines, and as-needed SABA (short-acting beta-2 agonist) therapy are appropriate alternatives to trial first. Montelukast remains a valid choice if the patient is counseled, understands the risks, and prefers it, but it is not the default first choice for mild disease.
Option A: Option A is incorrect because the neuropsychiatric boxed warning applies to all age groups, including young adults; age over 65 and pre-existing cardiac disease are not the qualifying conditions — the warning is universally applicable; and the warning explicitly requires counseling for all patients initiated on montelukast.
Option C: Option C is incorrect because the boxed warning concerns neuropsychiatric events, not irreversible bronchoconstriction; montelukast is not required to be co-administered with ICS and is not absolutely contraindicated as monotherapy in mild asthma — it is an approved alternative at GINA Step 2, though the warning recommends trying other therapies first for mild disease.
Option D: Option D is incorrect because hepatocellular injury requiring liver function test monitoring is associated with zileuton (a 5-LOX inhibitor), not with montelukast; montelukast does not carry a hepatotoxicity warning and does not require baseline or periodic LFT monitoring.
Option E: Option E is incorrect because the systemic vasculitis resembling Churg-Strauss syndrome upon corticosteroid tapering is a concern historically raised with zafirlukast, not montelukast; and the montelukast boxed warning for neuropsychiatric events is not limited to patients on concurrent systemic corticosteroids.
10. A pulmonologist initiates zileuton (Zyflo CR) as an add-on controller agent in a 35-year-old woman with aspirin-exacerbated respiratory disease (AERD) and moderate asthma. Which of the following correctly identifies the hepatic monitoring requirement for zileuton and the contraindication threshold that would preclude its initiation or require its discontinuation?
A) Zileuton requires no routine liver function test monitoring; hepatotoxicity occurs only in patients with pre-existing hepatic disease, and baseline liver enzymes within the normal range at initiation reliably identify patients who will not develop hepatocellular injury during therapy
B) Zileuton requires monitoring of liver function tests at baseline only; if the baseline is normal, subsequent monitoring is not necessary because the risk of hepatotoxicity is restricted to the first two weeks of therapy and resolves spontaneously in all cases
C) Zileuton requires liver function test monitoring at baseline and at one year; the contraindication threshold is any elevation above the upper limit of normal (ULN), including elevations within the clinically normal but elevated range, because zileuton hepatotoxicity is unpredictable and irreversible once it begins
D) Zileuton carries a neuropsychiatric boxed warning identical to montelukast's; liver function monitoring is a precautionary measure recommended but not required by the FDA label; the contraindication applies only when liver enzymes exceed 10 times the upper limit of normal in the setting of jaundice
E) Zileuton requires liver function test monitoring at baseline, monthly for the first three months, every two to three months for the remainder of the first year, and periodically thereafter; it is contraindicated in patients with active hepatic disease or liver enzyme elevations greater than three times the upper limit of normal (ULN) at baseline or during therapy
ANSWER: E
Rationale:
Zileuton causes hepatocellular injury in a small but clinically significant percentage of patients, necessitating a structured liver function test (LFT) monitoring schedule defined in the FDA prescribing information: baseline measurement before initiation, monthly for the first three months of therapy, every two to three months for the remainder of the first year, and periodically thereafter in patients on long-term therapy. Zileuton is contraindicated in patients with active hepatic disease or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevations greater than three times the upper limit of normal (ULN) at baseline; if LFTs rise to this threshold during therapy, zileuton should be discontinued. This monitoring requirement substantially distinguishes zileuton from the CysLT1 antagonists montelukast and zafirlukast, neither of which require routine LFT monitoring.
Option A: Option A is incorrect because zileuton hepatotoxicity can develop in patients with normal baseline liver function; baseline normality does not identify patients who will remain injury-free, and routine monitoring throughout the first year is explicitly required by the prescribing information.
Option B: Option B is incorrect because the monitoring requirement extends well beyond the initial weeks — the full schedule covers the entire first year and beyond; the statement that hepatotoxicity resolves spontaneously in all cases is also incorrect, as clinically significant hepatocellular injury requires drug discontinuation and does not invariably resolve spontaneously while drug is continued.
Option C: Option C is incorrect because the contraindication threshold is greater than three times the ULN (not any elevation above normal); mild elevations within one to two times the ULN do not automatically contraindicate zileuton initiation but require clinical judgment and more frequent monitoring; the monitoring schedule specified (baseline and one year only) omits the required monthly and quarterly intervals.
Option D: Option D is incorrect because the neuropsychiatric boxed warning is associated with montelukast, not zileuton; zileuton's boxed warning concerns hepatotoxicity; the LFT monitoring requirement is explicitly mandated in the FDA label and is not merely precautionary; and the 10× ULN threshold with jaundice is not the established zileuton contraindication threshold — the threshold is 3× ULN.
11. A 48-year-old man with severe asthma is being managed on oral theophylline, achieving a serum concentration of 13 mcg/mL. His pulmonologist adds zileuton for additional leukotriene pathway suppression. The physician correctly recognizes a clinically important drug interaction. Which of the following most accurately describes the mechanism, magnitude, and required management of this interaction?
A) Zileuton induces CYP3A4 (cytochrome P450 3A4) through pregnane X receptor (PXR) activation, accelerating theophylline metabolism through its minor CYP3A4 pathway and reducing serum theophylline concentrations by approximately 20–30%; the theophylline dose should be increased modestly and levels rechecked in two to three weeks
B) Zileuton competitively inhibits theophylline's active renal tubular secretion by occupying shared organic cation transporters in the proximal tubule, reducing urinary theophylline excretion; the clinical effect is modest (10–15% increase in theophylline levels) and does not typically require dose adjustment in patients whose baseline level is in the lower half of the therapeutic range
C) Zileuton inhibits CYP1A2 (cytochrome P450 1A2), the primary enzyme responsible for theophylline hepatic metabolism; co-administration can approximately double theophylline serum concentrations within days, requiring a theophylline dose reduction of approximately 50% and careful serum level monitoring to avoid toxicity
D) Zileuton and theophylline are both substrates for CYP1A2 and compete for the same enzyme active site; theophylline concentrations fall initially as zileuton preferentially occupies CYP1A2, but return to near-baseline after two to three weeks as CYP1A2 expression upregulates in response to increased substrate burden
E) Zileuton inhibits CYP2C9 (cytochrome P450 2C9) selectively; since theophylline has a minor metabolic pathway through CYP2C9, the interaction produces a clinically insignificant 5–10% rise in theophylline levels that does not require routine dose adjustment or additional serum level monitoring
ANSWER: C
Rationale:
Zileuton is metabolized by CYP1A2, CYP2C9, and CYP3A4 and inhibits CYP1A2 at clinical concentrations. Because CYP1A2 is the primary enzyme responsible for theophylline hepatic metabolism (accounting for more than 90% of clearance), zileuton's CYP1A2 inhibition substantially reduces theophylline clearance. The magnitude of this interaction is clinically critical: co-administration of zileuton can approximately double theophylline serum concentrations within days, even without any theophylline dose change. At a baseline theophylline level of 13 mcg/mL, doubling would produce a concentration of approximately 26 mcg/mL — well into the toxic range where gastrointestinal, cardiac, and neurological adverse effects become likely. The required management is a proactive theophylline dose reduction of approximately 50% at the time zileuton is initiated, followed by careful serum theophylline level monitoring to confirm that concentrations remain within the therapeutic range. This interaction is one of the most clinically consequential in pulmonary pharmacology.
Option A: Option A is incorrect because zileuton inhibits (not induces) CYP enzymes; it does not activate the pregnane X receptor (PXR) to induce CYP3A4; the direction of the theophylline level change is upward (rising due to reduced clearance), not downward; and dose reduction rather than dose increase is required.
Option B: Option B is incorrect because theophylline is eliminated primarily by hepatic CYP1A2 metabolism (more than 90%), not by renal tubular secretion; organic cation transporter competition does not represent a clinically significant mechanism for this interaction; and the magnitude of the interaction (approximately doubling theophylline concentrations) is far greater than 10–15%, requiring active dose adjustment.
Option D: Option D is incorrect because zileuton inhibits CYP1A2 rather than competitively occupying it as a substrate causing theophylline displacement; theophylline concentrations rise (not fall) upon zileuton addition; and there is no autoinduction mechanism that normalizes theophylline clearance after 2–3 weeks of co-administration — the inhibitory effect persists.
Option E: Option E is incorrect because the clinically important zileuton-theophylline interaction occurs through CYP1A2 inhibition, not CYP2C9; theophylline's primary metabolic pathway is CYP1A2 (not CYP2C9), so characterizing this as a minor pathway interaction dramatically understates the interaction's magnitude and clinical significance.
12. A 46-year-old woman with confirmed AERD (aspirin-exacerbated respiratory disease) develops osteoarthritis and requires regular analgesic and anti-inflammatory therapy. Her rheumatologist asks whether celecoxib is safe to use. Which of the following correctly explains the pharmacological basis for celecoxib's relative safety in AERD and accurately contrasts it with the cross-reactivity pattern among non-selective NSAIDs (non-steroidal anti-inflammatory drugs)?
A) AERD cross-reactivity among non-selective NSAIDs is pharmacological rather than immunological: all agents that inhibit COX-1 (cyclooxygenase-1) at anti-inflammatory doses reduce PGE2 (prostaglandin E2) synthesis, removing EP2 (prostaglandin E2 receptor subtype 2)-mediated restraint on 5-LOX (5-lipoxygenase) activity and triggering a cysteinyl leukotriene surge regardless of the NSAID's chemical structure; celecoxib is generally safe at standard doses because its COX-2 (cyclooxygenase-2) selectivity spares COX-1-mediated PGE2 production, preserving the EP2-mediated inhibitory tone on mast cell and eosinophil 5-LOX activity; caution is still warranted at high celecoxib doses where residual COX-1 activity may be sufficient to trigger reactions in patients with severe AERD
B) AERD cross-reactivity is IgE-mediated and specific to aspirin's salicylate chemical structure; agents with different chemical backbones — including ibuprofen, naproxen, and celecoxib — do not cross-react because they lack the salicylate epitope recognized by AERD-specific IgE antibodies; celecoxib is safe because it is chemically distinct from aspirin
C) All NSAIDs including celecoxib are equally contraindicated in AERD regardless of their COX selectivity profile because COX-2 inhibition itself triggers a compensatory upregulation of COX-1, which paradoxically produces a greater reduction in PGE2 than non-selective NSAID inhibition; celecoxib is therefore more dangerous than ibuprofen in AERD patients
D) Celecoxib is safe in AERD because it inhibits 5-LOX directly in addition to its COX-2 selectivity, and the 5-LOX inhibition compensates for any residual COX-1 suppression that might otherwise trigger leukotriene overproduction; non-selective NSAIDs lack this 5-LOX inhibitory component and therefore produce uncompensated leukotriene surges
E) AERD cross-reactivity is restricted to intravenous NSAIDs (ketorolac, indomethacin IV) and high-dose oral aspirin; standard oral doses of ibuprofen, naproxen, and diclofenac do not inhibit COX-1 sufficiently to reduce PGE2 and are generally safe for patients with AERD without special precautions
ANSWER: A
Rationale:
The cross-reactivity pattern in AERD is defined entirely by COX-1 inhibitory potency, not by chemical structure. AERD is not an IgE-mediated allergic reaction — there is no specific antigen and no aspirin-specific IgE antibody. The mechanism is pharmacological: COX-1 inhibition reduces PGE2 synthesis, removing PGE2's normal EP2 receptor-mediated restraint on mast cell and eosinophil 5-LOX activity, shunting arachidonic acid toward cysteinyl leukotriene synthesis and producing the clinical reaction. Any NSAID that inhibits COX-1 at anti-inflammatory concentrations — ibuprofen, naproxen, indomethacin, ketorolac, diclofenac — produces this effect and cross-reacts, regardless of chemical class. Celecoxib's relative safety derives from its COX-2 selectivity: at standard therapeutic doses, celecoxib spares COX-1-mediated PGE2 production in mast cells and airway mucosa, preserving the EP2-mediated inhibitory tone on 5-LOX. However, COX-2 inhibitors retain some residual COX-1 activity at higher doses, and caution is warranted in patients with very severe AERD — a small number of highly sensitive patients may react even to standard-dose celecoxib.
Option B: Option B is incorrect because AERD is not IgE-mediated and does not involve recognition of the salicylate chemical structure; ibuprofen and naproxen — propionic acid derivatives with entirely different chemical structures from aspirin — are potent COX-1 inhibitors that reliably trigger AERD reactions; their chemical dissimilarity from aspirin provides no protection.
Option C: Option C is incorrect because celecoxib does not produce compensatory COX-1 upregulation; COX-2 selectivity reduces, not increases, the pharmacological trigger for AERD; celecoxib is not more dangerous than ibuprofen in AERD — the clinical evidence and mechanistic rationale clearly support its comparative safety at standard doses.
Option D: Option D is incorrect because celecoxib does not inhibit 5-LOX; celecoxib is a selective COX-2 inhibitor with no direct 5-LOX inhibitory activity; 5-LOX inhibition is the mechanism of zileuton, not celecoxib; celecoxib's safety in AERD is attributable to COX-1 sparing, not to any upstream leukotriene synthesis inhibition.
Option E: Option E is incorrect because ibuprofen, naproxen, and diclofenac at standard oral anti-inflammatory doses are effective COX-1 inhibitors that reliably reduce PGE2 and trigger AERD reactions; the restriction of cross-reactivity to intravenous or high-dose preparations is pharmacologically inaccurate — standard oral doses are well established as AERD triggers.
13. A 52-year-old man with AERD (aspirin-exacerbated respiratory disease), recurrent nasal polyposis, and coronary artery disease requiring daily antiplatelet therapy is referred for aspirin desensitization at a specialized center. Which of the following correctly describes the aspirin desensitization procedure — including starting dose, endpoint, proposed mechanism, and the critical maintenance requirement — and explains why this patient is a particularly appropriate candidate?
A) Aspirin desensitization is performed by administering a single intramuscular dose of aspirin lysinate (300 mg) in a monitored setting; if the patient tolerates this without bronchospasm over a four-hour observation period, tolerance is established permanently and the patient may use any COX-1 (cyclooxygenase-1)-inhibiting NSAID (non-steroidal anti-inflammatory drug) without restriction indefinitely and without any maintenance regimen
B) Aspirin desensitization is contraindicated in patients with coronary artery disease because the procedure requires the patient to experience a controlled aspirin reaction — including transient bronchoconstriction and nasal congestion — which poses an unacceptable risk of demand ischemia in patients with reduced coronary reserve; alternative NSAID-avoidance strategies should be pursued exclusively
C) Aspirin desensitization involves administering progressively higher doses of intravenous ketorolac rather than oral aspirin, because oral aspirin produces unpredictable gastrointestinal absorption kinetics in AERD patients with nasal polyposis; tolerance is established when the patient tolerates a full IV ketorolac anti-inflammatory dose without bronchoconstriction
D) Aspirin desensitization involves supervised graded oral aspirin challenge beginning at very low doses (typically 30–60 mg) with incremental increases over one to three days in a controlled setting with resuscitation equipment available, until tolerance to full therapeutic aspirin doses is achieved; proposed mechanisms include CysLT1 (cysteinyl leukotriene receptor 1) receptor downregulation and EP2 (prostaglandin E2 receptor subtype 2) upregulation; the tolerant state is not permanent — it reverses within days of aspirin discontinuation and requires continuous daily aspirin use to maintain; this patient's concurrent coronary artery disease requiring antiplatelet therapy makes him an especially strong candidate, as successful desensitization allows safe therapeutic aspirin use
E) Aspirin desensitization is appropriate only for patients with AERD whose sole indication is nasal polyposis; it is not performed in patients who also require aspirin for cardiovascular indications because the cardiovascular aspirin dose (81 mg) is too low to maintain the desensitized state, and the anti-inflammatory aspirin dose (325–650 mg) required for maintenance exceeds safe cardiovascular dosing thresholds
ANSWER: D
Rationale:
Aspirin desensitization is a specialized procedure performed at centers experienced in managing AERD. It involves graded oral aspirin challenge beginning at very low doses — typically 30–60 mg — with incremental dose increases over one to three days in a setting with full resuscitation capability, because controlled aspirin-provoked reactions (bronchoconstriction, nasal symptoms) are expected during the initial challenge phase. The endpoint is tolerance to full therapeutic aspirin doses, typically 325–650 mg twice daily for maintenance. The proposed mechanisms include downregulation of CysLT1 receptors on mast cells and eosinophils, desensitization of mast cell responsiveness to CysLT1 signaling, and possible upregulation of the EP2 prostaglandin receptor — restoring partial PGE2-mediated inhibitory tone on 5-LOX (5-lipoxygenase) activity. The critical clinical feature is that the tolerant state is not permanent: it reverses within days of aspirin discontinuation. Continuous daily aspirin use is therefore mandatory to maintain desensitization; any gap in dosing requires repeat desensitization before aspirin can be safely resumed. This patient is an exceptionally strong desensitization candidate: his coronary artery disease requires antiplatelet therapy, making aspirin both medically necessary and currently inaccessible due to AERD — desensitization resolves this clinical dilemma by establishing tolerance that allows ongoing therapeutic aspirin use.
Option A: Option A is incorrect because desensitization is not achieved by a single intramuscular injection; it requires graded oral challenge over one to three days; tolerance is not permanent and requires continuous maintenance dosing; and the claim that tolerance extends to all COX-1-inhibiting NSAIDs indefinitely without maintenance is incorrect.
Option B: Option B is incorrect because coronary artery disease is not a contraindication to aspirin desensitization — it is actually one of the strongest clinical indications; the procedure is carefully controlled to minimize the severity of provoked reactions, and demand ischemia from the brief, monitored bronchospasm during low-dose challenge is not a standard reason to deny patients with CAD (coronary artery disease) access to desensitization.
Option C: Option C is incorrect because aspirin desensitization uses graded oral aspirin, not intravenous ketorolac; ketorolac IV is not the agent or route used in established aspirin desensitization protocols; gastrointestinal absorption variability in AERD patients with nasal polyposis is not the rationale for any route substitution.
Option E: Option E is incorrect because concurrent cardiovascular aspirin indication is one of the strongest indications for desensitization (not a contraindication); maintenance doses of 325–650 mg twice daily are the established therapeutic aspirin doses used after desensitization, and these doses are compatible with continued cardiovascular protection; the premise that cardiovascular and anti-inflammatory aspirin doses are incompatible for maintenance is clinically inaccurate.
14. A second-year resident asks about the pharmacological basis for cromolyn sodium's strict prophylactic-only use requirement and why this fundamental mechanistic property explains its near-obsolescence in adult asthma management. Which of the following most precisely describes cromolyn's mechanism, its consequent limitation, and the evidence basis for its displaced role?
A) Cromolyn sodium is a competitive antagonist at mast cell surface IgE receptors (FcεRI), preventing allergen-IgE crosslinking and the downstream degranulation cascade; because it competes reversibly with IgE for receptor occupancy, it must be administered before allergen exposure to occupy sufficient receptors before IgE concentrations rise; it is displaced from clinical use because omalizumab achieves the same IgE-receptor blockade with monthly dosing
B) Cromolyn sodium stabilizes mast cells by blocking chloride channels on the mast cell surface, preventing the calcium influx and membrane depolarization required for exocytosis of secretory granules; because it acts on the activation mechanism rather than on released mediators, it has no ability to reverse established bronchoconstriction — it cannot relax already-contracted airway smooth muscle or neutralize mediators already released; its clinical role has contracted because multiple controlled trials demonstrated that low-dose ICS (inhaled corticosteroids) provides superior asthma control, greater reduction in airway hyperresponsiveness, and better exacerbation prevention across all age groups in adults
C) Cromolyn sodium is a prodrug that is hydrolyzed by airway epithelial esterases to its active form, which then chelates calcium ions in the airway lumen before they can enter mast cells through calcium-release activated channels; this chelation mechanism is saturable and is overwhelmed by the calcium concentrations present during an active bronchospastic episode, explaining why pre-treatment is required and why the drug fails during established bronchoconstriction
D) Cromolyn sodium directly inhibits 5-LOX (5-lipoxygenase) in mast cells, reducing cysteinyl leukotriene synthesis before allergen exposure; once an acute bronchoconstriction episode begins, leukotriene synthesis is driven by a positive feedback loop that overwhelms cromolyn's inhibitory capacity, explaining why it fails therapeutically once symptoms have begun
E) Cromolyn sodium blocks the histamine H1 receptor on airway smooth muscle rather than preventing mediator release from mast cells; its prophylactic requirement reflects the time needed to achieve adequate receptor occupancy in airway tissue, and its limited efficacy in adults reflects the availability of second-generation antihistamines with superior H1 receptor affinity and longer duration of action
ANSWER: B
Rationale:
Cromolyn sodium's mechanism — blocking chloride channels on the mast cell surface — explains both its clinical utility and its fundamental limitation with pharmacological precision. The chloride channel blockade prevents the membrane potential changes that allow calcium influx through calcium-release activated channels (CRAC channels); without this calcium signal, the protein kinase C activation and cytoskeletal rearrangement required for granule exocytosis do not occur. This means cromolyn acts entirely upstream of mediator release: it can prevent degranulation if present before activation, but once degranulation has occurred — histamine, leukotrienes, and prostaglandins have already been released into the airway — cromolyn has no pharmacological mechanism to reverse bronchoconstriction or neutralize circulating mediators. This is the mechanistic basis for the prophylactic-only requirement. The near-obsolescence in adult asthma reflects the accumulated evidence that low-dose ICS provides superior outcomes — greater reduction in airway hyperresponsiveness, better exacerbation prevention, more effective symptom control — along with the practical limitation of cromolyn's four-times-daily dosing requirement.
Option A: Option A is incorrect because cromolyn does not block IgE receptors (FcεRI); it acts downstream of IgE-receptor crosslinking at the mast cell membrane activation mechanism; FcεRI blockade is the mechanism of therapeutic targets like omalizumab (anti-IgE antibody), not cromolyn; the competitive IgE-receptor antagonist mechanism described is pharmacologically inaccurate.
Option C: Option C is incorrect because cromolyn is not a prodrug and does not work by chelating extracellular calcium ions in the airway lumen; it is pharmacologically active as administered and acts intracellularly at chloride channels on the mast cell membrane; the saturable calcium chelation mechanism described does not reflect established cromolyn pharmacology.
Option D: Option D is incorrect because cromolyn does not inhibit 5-LOX; its mechanism is mast cell stabilization via chloride channel blockade, not leukotriene synthesis inhibition; 5-LOX inhibition is the mechanism of zileuton; and there is no established positive feedback loop that selectively overwhelms 5-LOX inhibition during active bronchoconstriction.
Option E: Option E is incorrect because cromolyn does not block histamine H1 receptors on airway smooth muscle; it is not an antihistamine; its mechanism is entirely at the mast cell membrane level, preventing mediator release rather than blocking mediator action at target tissues; H1 receptor pharmacology has no relevance to cromolyn's mechanism or its clinical limitations.
15. A pulmonologist is teaching a medical student about the positioning of LTRAs (leukotriene receptor antagonists) in GINA (Global Initiative for Asthma) step therapy and the patient phenotypes where they provide the most clinically meaningful incremental benefit. Which of the following most accurately describes LTRA positioning in asthma step therapy and the clinical niches where they are specifically advantageous?
A) LTRAs are the preferred first-line controller agents at GINA Step 2, recommended over low-dose ICS (inhaled corticosteroids) for all patients with mild persistent asthma because their oral route of administration ensures higher adherence and more predictable drug delivery than inhaled therapy; ICS is reserved for patients who fail LTRA monotherapy
B) LTRAs are not included at any step of the GINA asthma treatment ladder because the combination of the FDA neuropsychiatric boxed warning for montelukast and the warfarin interaction risk for zafirlukast has led to a formal GINA recommendation to avoid all LTRA use in favor of ICS and biologic agents
C) LTRAs have equivalent anti-inflammatory efficacy to low-dose ICS at GINA Step 2 and are interchangeable with ICS as first-line controllers; the choice between them should be made entirely on patient preference for inhaled versus oral therapy, with no difference in expected exacerbation prevention or lung function outcomes
D) LTRAs are appropriate at all GINA steps as the primary controller agent and offer the additional advantage of simultaneously treating asthma and allergic rhinitis without requiring separate medications; their dual airway benefit makes them superior to ICS at every step from Step 2 through Step 5 in patients with combined asthma-rhinitis phenotype
E) At GINA Step 2, LTRAs are an alternative — but consistently less effective than low-dose ICS — for patients who cannot or will not use inhaled therapy; at Step 3 and above they serve as add-on agents to ICS or ICS/LABA (long-acting beta-2 agonist) combinations; specific niches where they provide disproportionate benefit include exercise-induced bronchoconstriction, AERD (aspirin-exacerbated respiratory disease), and combined asthma-allergic rhinitis phenotypes
ANSWER: E
Rationale:
LTRAs occupy a well-defined and limited role in asthma step therapy, not a first-line position. At GINA Step 2, LTRAs are an alternative controller option for patients who cannot use or strongly prefer to avoid inhaled therapy, but multiple controlled trials — most notably the Price et al. NEJM 2011 pragmatic trial comparing LTRA monotherapy to ICS — have established that LTRAs are consistently inferior to low-dose ICS for most patients at Step 2 in reducing exacerbations and improving lung function; ICS remains the preferred controller at Step 2. At Step 3 and above, LTRAs add incremental benefit as add-on agents to ICS or ICS/LABA combinations through pharmacological complementarity — blocking the leukotriene pathway while ICS suppresses the broader inflammatory cascade. Specific clinical niches where LTRAs provide disproportionate benefit: exercise-induced bronchoconstriction (EIB), where pre-exercise LTRA dosing suppresses EIB through CysLT1 blockade; AERD, where LTRAs directly target the CysLT1 receptors activated by the COX-1 inhibition-driven leukotriene surge; and combined asthma-allergic rhinitis phenotypes, where a single oral agent addresses both upper and lower airway components.
Option A: Option A is incorrect because LTRAs are not the preferred agents at GINA Step 2 — ICS is the preferred first-line controller; LTRAs are listed as alternatives, not preferred agents; adherence advantages of oral administration do not overcome the demonstrated efficacy inferiority to ICS in asthma control outcomes.
Option B: Option B is incorrect because LTRAs remain included in GINA guidelines as alternative or add-on controller agents; the FDA neuropsychiatric boxed warning for montelukast led to a recommendation to weigh risks carefully for mild disease, not to avoid all LTRA use; GINA has not issued a blanket recommendation to avoid the LTRA class.
Option C: Option C is incorrect because LTRAs and low-dose ICS are not interchangeable at Step 2 — multiple controlled trials have demonstrated ICS superiority in reducing exacerbations and improving lung function; characterizing them as equivalent anti-inflammatory agents contradicts the established evidence base including the Price et al. pragmatic trial.
Option D: Option D is incorrect because LTRAs are not the primary controller at any GINA step — they are alternative or add-on agents; characterizing them as superior to ICS at every step from Step 2 through Step 5 in patients with combined asthma-rhinitis inverts the established hierarchy; ICS remains the foundation of asthma controller therapy at all steps where anti-inflammatory treatment is indicated.
16. A 55-year-old woman with COPD (chronic obstructive pulmonary disease) on chronic theophylline therapy presents to the emergency department following intentional ingestion of her entire theophylline supply. Her serum theophylline level is 68 mcg/mL; she has persistent vomiting, a ventricular rate of 148 beats per minute on ECG, and is becoming increasingly agitated. Which of the following correctly identifies the appropriate acute management strategy and the specific theophylline concentration thresholds that establish hemodialysis as an indicated intervention?
A) Intravenous sodium bicarbonate is the first-line intervention for theophylline overdose because theophylline is a weak acid whose ionization is pH-dependent; alkalinization of the urine with bicarbonate traps ionized theophylline in the renal tubule and accelerates urinary elimination; hemodialysis is indicated only when the theophylline level exceeds 100 mcg/mL regardless of clinical symptoms
B) Single-dose activated charcoal administered orally within one hour of ingestion is the only gastrointestinal decontamination strategy with established evidence in theophylline overdose; multi-dose activated charcoal has no role because theophylline does not undergo enterohepatic recirculation; hemodialysis is indicated when serum levels exceed 50 mcg/mL in all patients regardless of clinical symptoms
C) Gastrointestinal decontamination with multi-dose oral activated charcoal is effective in enhancing theophylline elimination by interrupting enterohepatic recirculation; hemodialysis is indicated when serum theophylline concentrations exceed 90 mcg/mL in acute overdose, exceed 40–60 mcg/mL in chronic toxicity, or at any concentration in a patient with life-threatening arrhythmia or refractory seizures; this patient's level of 68 mcg/mL combined with ventricular tachycardia meets the threshold for urgent hemodialysis
D) Physostigmine should be administered intravenously to reverse theophylline's CNS (central nervous system) and cardiac toxicity through cholinergic re-activation at the AV (atrioventricular) node and adrenergic receptor blockade; activated charcoal is contraindicated in theophylline overdose because it binds theophylline irreversibly and can precipitate complete theophylline toxicity by releasing a concentrated drug bolus during gastrointestinal transit
E) Beta-blocker therapy (propranolol) is the definitive antidote for theophylline-induced tachyarrhythmias and should be administered first before any decontamination strategy; hemodialysis is not effective for theophylline removal because theophylline is highly protein-bound and cannot be efficiently dialyzed across a conventional hemodialysis membrane
ANSWER: C
Rationale:
Theophylline overdose management centers on gastrointestinal decontamination and extracorporeal removal. Multi-dose activated charcoal (MDAC) administered orally or via nasogastric tube is effective not only for initial GI decontamination but also for enhancing ongoing theophylline elimination by interrupting enterohepatic recirculation — theophylline secreted into bile and the GI lumen is adsorbed by repeated charcoal doses before it can be reabsorbed. Hemodialysis is highly efficient at theophylline removal and is indicated based on both concentration thresholds and clinical presentation: serum levels above 90 mcg/mL in acute overdose, above 40–60 mcg/mL in chronic toxicity (where tolerance may be lower), or at any concentration in a patient with life-threatening arrhythmia or refractory seizures. This patient's theophylline level of 68 mcg/mL combined with apparent ventricular tachyarrhythmia and progressive neurological deterioration clearly meets the threshold — hemodialysis should be initiated urgently.
Option A: Option A is incorrect because urinary alkalinization with sodium bicarbonate is the elimination strategy for weak acids excreted by the kidney (such as salicylate and phenobarbital); theophylline is eliminated primarily by hepatic CYP1A2 metabolism (more than 90%), not by renal excretion, so urinary pH manipulation does not significantly enhance theophylline elimination; the threshold of 100 mcg/mL regardless of clinical symptoms also underestimates the indication for dialysis.
Option B: Option B is incorrect because multi-dose activated charcoal has established efficacy in theophylline overdose specifically because theophylline does undergo enterohepatic recirculation — a single dose would be insufficient; the threshold of 50 mcg/mL in all patients regardless of clinical symptoms does not accurately reflect the established graduated threshold that also considers chronicity of exposure and clinical severity.
Option D: Option D is incorrect because physostigmine is used to reverse anticholinergic toxidrome (not theophylline toxicity); theophylline's mechanism involves adenosine receptor antagonism and catecholamine excess, not anticholinergic receptor blockade; and activated charcoal is not contraindicated in theophylline overdose — it is a cornerstone of management; the described mechanism of irreversible binding followed by concentrated release during GI transit is pharmacologically implausible.
Option E: Option E is incorrect because hemodialysis is actually highly effective for theophylline removal — theophylline is only approximately 40% protein-bound (not highly protein-bound), has a relatively small volume of distribution, and is efficiently cleared by conventional hemodialysis; beta-blockers may have a role in managing specific arrhythmias in theophylline toxicity but are not the definitive first-line antidote and should not take precedence over decontamination and extracorporeal removal in a severely toxic patient.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.